Close Menu

NEW YORK — French diagnostics firm Novacyt on Thursday posted a more than 900 percent year-over-year jump in revenues for the first half of 2020 due to strong sales of its PCR-based SARS-CoV-2 test and related products.

For the six-month period ended June 30, Novacyt's revenues were €72.4 million ($85.4 million) versus €7.2 million a year earlier, in line with preliminary revenue figures the company provided in July. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.